Apyx Medical Corporation Q3 2024 Financial Review
Apyx Medical Corporation (NASDAQ: APYX), known for its innovative helium plasma platform technology marketed as Renuvion®, has unveiled its financial results for the third quarter of 2024. As the company navigates through a challenging environment, it has also updated its financial outlook for the rest of the year and introduced expectations for 2025.
Financial Highlights from Q3
During the quarter, Apyx recorded total revenue of $11.5 million, reflecting a 4% decrease compared to the previous year. This figure comprises $9.3 million from Advanced Energy, which saw a 6% decline, and $2.2 million from OEM revenue, marking a 3% growth. Despite ongoing economic pressures, the company remains confident in its growth trajectory.
Strategic Moves to Strengthen Operations
To bolster its operational efficiency, Apyx Medical launched a cost-saving restructuring program that includes a significant workforce reduction of approximately 25%. These measures are anticipated to generate annual savings of about $4.3 million.
Growth in Single-Use Handpiece Revenue
One of the bright spots in Apyx's recent performance was a 9% overall growth in single-use handpiece revenue, with particularly strong results in the U.S. market, where growth reached 15%. This trend underscores the increasing adoption of Apyx's products in the market.
Balance Sheet and Funding Updates
Apyx Medical successfully closed a $7.0 million registered direct offering to enhance its balance sheet. Furthermore, the credit agreement with Perceptive Credit Holdings was amended to lower revenue covenants and adjust operating expense limits for 2025 and 2026, allowing greater flexibility for strategic initiatives.
Operational Outlook and Upcoming Innovations
Looking ahead, Apyx anticipates continued strength in disposable handpiece sales, expecting to ship nearly 90,000 units for the full year 2024. Additionally, the development of the Ayon body contouring system is nearing completion, promising to be a game-changer in the aesthetic surgical landscape.
Financial Guidance for 2024 and Beyond
The company has adjusted its revenue expectations for the full year 2024, now projecting a total between $46.6 million and $47.6 million, down from previous estimates. For 2025, Apyx Medical forecasts revenues to grow slightly, estimating a range of $47.6 million to $49.5 million. This cautious optimism reflects a comprehensive assessment of market conditions and company performance.
CEO's Perspective on Current Operations
Charlie Goodwin, President and CEO, expressed satisfaction with the performance of the disposable handpiece segment and emphasized the importance of the recently implemented restructuring measures. He noted that these actions aim to position Apyx Medical for sustainable growth while effectively managing costs.
Frequently Asked Questions
What were Apyx Medical Corporation's total revenues for Q3 2024?
The total revenues for Q3 2024 were $11.5 million, which represented a 4% decrease year-over-year.
What strategic actions did Apyx Medical implement in Q3?
Apyx Medical announced a restructuring program that involved nearly a 25% reduction in its U.S. workforce to streamline operations and improve efficiency.
What are the expected revenue numbers for full-year 2024?
The company expects total revenue for 2024 to be between $46.6 million and $47.6 million.
What is Apyx Medical Corporation's outlook for 2025?
For 2025, the company anticipates revenue between $47.6 million and $49.5 million, indicating growth of approximately 2% to 6% compared to 2024.
What product developments is Apyx Medical working on?
Apyx Medical is in the final stages of developing the Ayon body contouring system, which integrates multiple aesthetic technologies into a single platform.
